This trial will assess the tolerability and safety of AFX-2 over a range of five dose levels
in adults with low-, intermediate- or high-risk Chronic Lymphocytic Leukemia (CLL). The trial
will also determine the impact of dose on quality of life indices and on biological and
immune responses, and will assess if there is a maximum tolerated dose and/or dose-limiting
toxicity in this study population.